Eli Lilly's Zepbound Becomes First FDA-Approved Drug Therapy for Sleep Apnea
The FDA approved Eli Lilly's tirzepatide (Zepbound) for moderate-to-severe obstructive sleep apnea (OSA) in adults with obesity, to be used with a reduced-calorie diet and exercise. Zepbound, a once-weekly injectable, reduces body weight, which improves OSA, and is the first drug therapy for this condition. It showed significant reduction in breathing disruptions per hour and weight loss in clinical trials, posing a competitive challenge to CPAP device makers.
Highlighted Terms
Related News
The FDA approved Eli Lilly's tirzepatide (Zepbound) for moderate-to-severe obstructive sleep apnea (OSA) in adults with obesity, to be used with a reduced-calorie diet and exercise. Zepbound, a once-weekly injectable, reduces body weight, which improves OSA, and is the first drug therapy for this condition. It showed significant reduction in breathing disruptions per hour and weight loss in clinical trials, posing a competitive challenge to CPAP device makers.